Prospects of aprotinin application in maxillofacial surgery and dentistry (literature review)
DOI:
https://doi.org/10.11603/2311-9624.2017.1.7589Keywords:
aprotinin, kininogenase and proteolisis inhibitor, kallikrein-kinin system, fibrinolysis, maxillofacial area, inflammatory disease, dental surgery, maxillofacial surgery.Abstract
The article adduces the current experience of using of the aprotinin (inhibitor of proteolisis and kininogenesis) in the clinical medicine. We also highlighted the mechanism of its influence on the organizm and described the indications for it use with therapeutic purposes after surgical pain syndrome. We confirmed the effectivness of drugs based on aprotinin for the treatment in various pathological conditions, because of its anti-inflammatory, antifibrinolitic, antishock action. Nowadays, the drugs which contain the main active substance as aprotinin are used for the prevention and treatment of pancreatitis, pancreonecrosis, hyperfibrinolitic bleeding, complications after thrombolytic therapy and in cardiac surgery. Injection of aprotinin before surgery helps to prevent the development of diffuse bleeding during operation. The anti-inflammatory mechanism of aprotinin has multivalent character. The ability of aprotinin to reduce the production of proinflammatory interleukines and at the same time stimulates the appearance of anti-inflammatory interleukins that allows to use it for reducing of surgery trauma and postoperative pain syndrome. In addition, we presented the results of local application of products containing aprotinin ("Gordoх", "Contrical", "Tachokomb", "Aerus"), used by the physiotherapy. In this article we analyzed recent literature data on the use of aprotinin in clinical dental practice and maxillofacial surgery (treatment of the maxillofacial area soft tissue inflammation, complications of bone fractures, impacted lower third molars surgery). The ability of the aprotinin to reduce the symptoms of inflammation, improve microcirculation, heal postoperative wounds and its positive impact on haemodynamics makes it an alternative to dexamethasone while dealing with the pain and swelling. All above mentioned serves as a base for more widespread application of aprotinin in practical of dentistry and maxillofacial surgery.
References
Ortmann, E., Besser, M. W., & Klein, A. A. (2013). Antifibrinolytic agents in current anaesthetic practice. British Journal of Anaesthesia, 111 (4), 549-563.
Paliy, I.I., Zaika, S.V., & Paliy D.V. (2007). Rol kalikrein-kininovoi systemy u rozvytku patolohichnykh staniv v orhanizmi liudyny ta mozhlyvi shliakhy yikh korektsii [The role of the kallikrein-kinin system in the development of pathological conditions in humans and possible ways of correction]. Medytsyna neotlozhnykh sostoianii – Emergency Medicine, 10, 21-25 [in Ukrainian].
Kubyshkin A.V., & Fomochkina I.I. (2009). Vplyv inhibitoriv proteiinaz na efektyvnist pryhnichennia aktyvatsii proteolizu pry zapalenni leheniv [Impact of protease inhibitors on the efficiency of suppression of activated proteolysis with pneumonia]. Fiziol. zhurn. – Physiological Journal, 55, (1), 43-48 [in Ukrainian].
Dementieva, I.I., Charnaia, M.A., & Morozov Yu.A. (2007). Aprotinin: bezopasnost primeneniia v khirurgicheskoi praktike: Obzor [Aprotinin, safety of use in surgical practice: Review]. Anestezyologiya i reanimatologiya – Anaestheziology and Reanimatology, 2, 69-71 [in Russian].
Fergusson, D.A., Hébert, P.C., & Mazer, C.D. (2008). A comparison of aprotinin and lysine analogues in high–risk cardiac surgery. The New England Journal of Medicine, 358 (22), 2319-2331.
Huberhryts, N.B., & Ahapova, N.H. (2004). Kupirovaniie boli pri khronicheskom pankreatite [Relief of pain in chronic pancreatitis]. Suchasna hastroenterolohiia - Contemporary Gastroenterology, 4, 13-24 [in Russian].
Henry, D.A., Carless, P.A. & Moxey, A.J. (2011). Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst. Rev. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001886.pub3/abstract;jsessionid=0ED8C4BF8D0845C4E30D0AE0FF0A13F9.f02t04.
Casati, V., Guzzon, D., & Oppizzi, M. (2000). Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J. Thorac. Cardiovasc. Surg., 120 (3), 520-527.
Huang, F., Zhao, Q. & Guo, C. (2014). Use of aprotinin to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis. Transfus. Apher. Sci., 51 (2), 152-161.
Bytkova, E.E., Tymerbaev, V.Kh., Khvatov, V.B., Zvereva, N.Yu., Chumakov, M.V., & Shumskiy, K.Yu. (2014). Vliianiie otechestvennykh preparatov-ingibitorov fibrinoliza na agregantnoie sostoyaniie krovi i obiem operatsionnoi krovopoteri u kardiokhirurgicheskikh bolnykh [Effect of domestic fibrinolysis inhibitor on aggregate blood state and capacity operative blood loss in patient after cardiac surgery]. Anesteziologiia i reanimatologiia – Anaestheziology and Reanimatology, 2, 59-64 [in Russian].
Osypova N.A., Eldarkhanov D.R., Khoronenko V.E., Khovanskaia T.P., Petrova V.V., & Alekseev B.Ya. (2012). Ingibitory fibrinoliza traneksamovaia kislota i aprotinin pri radikalnoi prostatektomii: prospektivnoie randomizirovannoie sravnitelnoie issledovaniye [Fibrinolysis inhibitors tranexamic acid and aprotinine: prospective randomized comparative study]. Anesteziologiia i reanimatologiia – Anaestheziology and Reanimatology, 5, 35-42 [in Russian].
Aprotinin: is it time to reconsider? / European Society of Anaesthesiology task force reports on place of aprotinin in clinical anaesthesia. European Journal of Anaesthesiology, 32 (9), 591-595.
Loshenko, I.A. (2016). Optymizatsiia vykorystannia inhibitoriv fibrynolizu v kompleksi intensyvnoi terapii akusherskykh krovotech vnaslidok peredchasnoho vidsharuvannia platsenty u peryoperatsiinomu periodi [Optimization of fibrinolysis inhibitor in complex intensive care obstetric hemorrhage due to placenta abruption in the perioperative period]. Candidate’s thesis. Odesa: ONMedU [in Ukrainian].
Podhaievskyi, S.H. (2006). Kliniko-biokhimichna otsinka zastosuvannia preparatu kontrykal v kompleksnomu likuvanni khvorykh na tuberkuloz lehen z suputnim khronichnym bronkhitom [Clinical and biochemical evaluation of the drug contrical in treatment of pulmonary tuberculosis patients with concomitant chronic bronchitis]. Extended abstract of candidate’s thesis. Kyiv: In-t ftyziatrii i pulmonolohii im. F.H.Yanovskoho AMN Ukrainy [in Ukrainian].
Shalmin, O.S., Yasinskyi, R.M., Rastvorov, O.A., Piroh A.I., & Hohlova K.P. (2014). Efektyvnist likuvannia VIL/SNID-asotsiiovanoho vpershe diahnostovanoho tuberkulozu lehen iz zastosuvanniam aprotyninu, hlutoksymu ta lazeroterapii [The effectiveness of treatment of HIV/AIDS associated newly diagnosed pulmonary tuberculosis with the use of aprotininum, glutoximand and laser]. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia: ukr. nauk.-prakt. zhurn. – Tuberculosis. Lung Diseases. HIV infection: Ukrainian Scientific-Practical Journal, 2, 25-30 [in Ukrainian].
Srebniak I.A. (2015). Aktyvnist proteiinaz v eksudati z serednoho vukha ta kholesteatomi do ta pislia kompleksnoho likuvannia [Proteinases activitity in ear disharge, cholesteatoma matrix and adjacent bone in patients with chronic otitis media before and different terms after complex treatment]. Zhurnal vushykh nosovykh i horlovykh khvorob – Journal of Ear, Nose and Throat Diseases, 1, 14-20 [in Ukrainian].
Rodin, A.Yu. (1996). Patogeneticheskoe obosnovanie i klinicheskaya effektivnost primeneniya estestvennykh ingibitorov proteaz v terapii psoriaza [Pathogenetic rationale and clinical efficacy of natural protease inhibitors in the treatment of psoriasis]. Vestn. dermatol. i venerol. – Journal of Dermatology and Venerology, 4, 36-38 [in Russian].
Zhirnov, O.P. (2012). Aprotinin. ingibitor proteaz – novaia alternativa v lechenii grippa [Aprotinin. Protease inhibitors – a new alternative in the treatment of influenza]. Rossiyskiy meditsinskiy zhurnal – Russian Medical Journal, 2, 52-56 [in Russian].
Zhirnov, O.P., Bokova N.O., Isaieva, E.I., Vorobieva, I.V., Konakova, T.E., & Malyshev, N.A (2014). Lechebnyi effekt aerozolnoi formy aprotinina pri grippe [Therapeutic effect of aerosol form of aprotinin against influenza]. Epidemiologiia i infektsionnyie bolezni – Epidemiology and Infectious Diseases, 6, 10-15 [in Russian].
Malyshev, N.A., Zhirnov, O.P., & Poiarkov, S.V. (2009). Antivirusnyie i protivovospalitelnyie misheni aprotinina: perspektivy novogo ispolzovaniya [Antiviral and antiinflammatory targets for aprotinin: perspectives of novel implementation]. Pulmonologiia – Pulmonology, 3, 109-118 [in Russian].
Berling, R., Borgstrom, A., & Ohlsson, K. (1998). Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors. Int. J. Pancreatol., 24 (1), 9-17.
Eren, S., Esme, H., & Balci, A. E. (2003). The effect of aprotinin on ischemia-reperfusion injury in an in situ normothermic ischemic lung model. Eur. J. Cardiothorac. Surg., 23 (1), 60-65.
Ostashevskii, V.L. (1984). Lechebnoie deistviie instilliatsii kontrikala pri gnoinom iazvennom keratite [The therapeutic effect of instillation kontrikala in purulent ulcerative keratitis]. Oftalmologicheskii zhurnal – Ophtalmological Journal, 6, 350-356 [in Russian].
Fayez, R.I. (1990). Vnutritkanevoi elektroforez essentsiale i kontrikala v lechenii bolnykh khronicheskim hepatitom i khronicheskim pankreatitom [Essentiale and kontrikal interstitial electrophoresis in patients with chronic hepatitis and chronic pancreatitis]. Extended abstract of candidate’s thesis. Minsk [in Russian].
Iftodii, A. Effects of constant-current electric field on tissue and plasma proteolysis in acute pancreatitis, Klin.Khir., 34-36.
Ulashchik V.S. (2010). Elektroforez lekarstvennykh veshchestv: rukovodstvo dlya spetsialistov [Electrophoresis of drugs: a guide for professionals]. Minsk: Navuka. [in Russian].
Beierlein, W., Scheule, A. M., Antoniadis, G. (2000). An immediate, allergic skin reaction to aprotinin after reexposure to fibrin sealant. Transfusion, 40 (3), 302-305.
Zorina, O.A. (2014). Pokazaniia i metodika primeneniia preparata «Takhokomb» pri mukogingivalnoi khirurgii patsiientov s metabolicheskim sindromom [Indications and methods for use of preparation tachocomb in mucogingival surgery in patients with metabolic syndrome]. Farmateka – Farmateka, 3, 14-18 [in Russian].
Sheremeta, E.A. (2012). Vozmozhnosti primeneniia «Takhokomba» pri vestibuloplastike [Application possibilities “Tahokomba” at vestibuloplasty]. Krymskii zhurnal eksperimentalnoi i klinicheskoi meditsiny – Crimean Journal of Experimental and Clinical Medicine, 3-4, 67-69 [in Russian].
Malanchuk, V.A., Kulbashna, Ya.A., & Mamonov, R.O. Patent 48776 U Ukraina. Sposib likuvannia hniino-zapalnykh zakhvoryuvan shchelepno-lytsevoi dilianky. Zaiavnyk ta patentovlasnyk Natsionalnyi medychnyi universytet imeni O.O. Bohomoltsia. u200913809; zaiavl. 29.12.2009; opubl. 25.03.2010, Byul. 6.
Demianova, I., Mamonov, R., (2012). Aprotynin v kompleksnomu likuvanni zapalnykh uskladnen perelomiv shchelepno-lytsevoii dilianky [Aprotinin in treatment of inflammatory complications of fractures of the maxillofacial area]. Ukrayinskyi naukovo-medychnyi molodizhnyi zhurnal – Ukrainian Scientific Medical Youth Journal, 3, 333 [in Ukrainian].
Brennan, P.A., Gardiner, G.T., & McHugh, J. (1991). A double blind clinical trial to assess the value of aprotinin in third molar surgery. Br. J. Oral Maxillofac. Surg., 29 (3), 176-179.
Jegadeesan, V.V. & Ponnaiyan, D. (2016). Impact of aprotinin – a proteolytic enzyme on postsurgical symptoms in patients undergoing third molar surgeries. J. Clin. Diagn. Res., 10 (1), 18-22.
Gururaj Arakeri, Kirthi Kumar Rai, Shivakumar, H. R. & Bhushan Jayade (2013). A randomized clinical trial to compare the efficacy of submucosal aprotinin injection and intravenous dexamethasone in reducing pain and swelling after third molar surgery: a prospective study. J. Maxillofac. Oral Surg., 12, 73-79.
